Treatment of tropical and parasitic diseases using medicines that are not licensed in Japa
Not Applicable
- Conditions
- Tropical diseases, parasitic diseases
- Registration Number
- JPRN-UMIN000004125
- Lead Sponsor
- niversity of Miyazaki, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 750
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are allergic to the drugs, patients for whom the possible disadvantages due to the drug adverse events may overweigh the advantages due to the drug's clinical effects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical effects and adverse events due to drug treatments
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of unlicensed antiparasitic drugs in JPRN-UMIN000004125 for leishmaniasis and schistosomiasis?
How does the therapeutic potential of JPRN-UMIN000004125's unlicensed compounds compare to standard-of-care treatments like artemisinin or ivermectin in tropical disease management?
Which biomarkers correlate with treatment response in JPRN-UMIN000004125 for parasitic infections such as malaria or filariasis?
What are the safety profiles and adverse event management strategies for off-label antiparasitic drugs tested in JPRN-UMIN000004125?
Are there synergistic combination therapies or repurposed pharmaceuticals evaluated in JPRN-UMIN000004125 for drug-resistant tropical diseases?